Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Emgality ® ▼ (galcanezumab)
Emgality® (galcanezumab) Pen: Information on Needle
The pre-filled pen comes with a 27 gauge (thin wall) x 12.7 mm permanently built in needle.
The needle is built into the cartridge that is inside the pen and cannot be changed or taken off. The needle or needle attachment must not be touched.1
The needle included in the pack is only suitable for subcutaneous injection.2
Dripping from the Needle
Pre-Filled Pen Function: Needle Retraction
When the medicine is completely delivered, the needle begins to travel upward (retract). The patient may feel the needle travel upwards in the pen. The second loud click is heard right before the needle stops retracting. The whole process of the needle retraction occurs very quickly.1
If the needle does not retract after the injection the needle must not be touched and the base cap must not be replaced. The pen must be stored in a safe place to avoid an accidental needlestick injury. Patients can contact their doctor, pharmacist or nurse for instructions on how to return the pen.3
The instructions for using the pen included with the Package Leaflet, must be followed carefully. The pre-filled pen is for total use only.2
After training, patients may self-inject galcanezumab if a healthcare professional determines that it is appropriate. 2
3. Emgality [instructions for use]. Eli Lilly Nederland B.V., The Netherlands.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: February 15, 2019